<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Background- Loss-of-function mutations in Nav1.5 cause <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:e sem="disease" ids="C1720983" disease_type="Disease or Syndrome" abbrv="">channelopathies</z:e>, including <z:e sem="disease" ids="C1142166" disease_type="Disease or Syndrome" abbrv="SUNDS">Brugada syndrome</z:e>, <z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo>, and <z:hpo ids='HP_0011704'>sick sinus syndrome</z:hpo>; however, no effective therapy exists </plain></SENT>
<SENT sid="1" pm="."><plain>MOG1 increases plasma membrane (PM) expression of Nav1.5 and <z:chebi fb="199" ids="26708">sodium</z:chebi> current (<z:chebi fb="0" ids="33167">INa</z:chebi>) density, thus we hypothesize that MOG1 can serve as a therapeutic target for <z:chebi fb="199" ids="26708">sodium</z:chebi> <z:e sem="disease" ids="C1720983" disease_type="Disease or Syndrome" abbrv="">channelopathies</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Methods and Results- Knockdown of MOG1 expression using small interfering <z:chebi fb="40" ids="33697">RNAs</z:chebi> reduced Nav1.5 PM expression, decreased <z:chebi fb="0" ids="33167">INa</z:chebi> densities by 2-fold in HEK/Nav1.5 cells and nearly abolished <z:chebi fb="0" ids="33167">INa</z:chebi> in mouse cardiomyocytes </plain></SENT>
<SENT sid="3" pm="."><plain>MOG1 did not affect Nav1.5 PM turnover </plain></SENT>
<SENT sid="4" pm="."><plain>MOG1 small interfering <z:chebi fb="40" ids="33697">RNAs</z:chebi> caused retention of Nav1.5 in endoplasmic reticulum, disrupted the distribution of Nav1.5 into caveolin-3-enriched microdomains, and led to redistribution of Nav1.5 to noncaveolin-rich domains </plain></SENT>
<SENT sid="5" pm="."><plain>MOG1 fully rescued the reduced PM expression and <z:chebi fb="0" ids="33167">INa</z:chebi> densities by Nav1.5 trafficking-defective mutation D1275N associated with <z:hpo ids='HP_0011704'>sick sinus syndrome</z:hpo>/<z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo>/atrial <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>For <z:e sem="disease" ids="C1142166" disease_type="Disease or Syndrome" abbrv="SUNDS">Brugada syndrome</z:e> mutation G1743R, MOG1 restored the impaired PM expression of the mutant protein and restored <z:chebi fb="0" ids="33167">INa</z:chebi> in a heterozygous state (mixture of <z:mp ids='MP_0002169'>wild type</z:mp> and mutant Nav1.5) to a full level of a homozygous <z:mp ids='MP_0002169'>wild-type</z:mp> state </plain></SENT>
<SENT sid="7" pm="."><plain>Conclusions- Use of MOG1 to enhance Nav1.5 trafficking to PM may be a potential personalized therapeutic approach for some patients with <z:e sem="disease" ids="C1142166" disease_type="Disease or Syndrome" abbrv="SUNDS">Brugada syndrome</z:e>, <z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo>, and <z:hpo ids='HP_0011704'>sick sinus syndrome</z:hpo> in the future </plain></SENT>
</text></document>